Whether Tarlatamab-Imdelltra is available in China and analysis of drug purchase channels in various places

Tarlatamab-Imdelltra is a new bispecific antibody drug mainly used for the treatment of specific advanced solid tumors. The drug activates the body's immune system to attack tumor cells by simultaneously targeting tumor-associated antigens and T cell surface CD3 molecules, thereby exerting anti-tumor effects. Clinical studies have shown that talatumumab can improve the objective response rate in specific patient groups and improve patients' quality of life within a safe and controllable range. As a newly launched immunotherapy drug, its efficacy and safety are still under continuous observation worldwide.

In the domestic market, talatumumab has not yet been officially launched, nor has it been included in medical insurance reimbursement items. This means that patients cannot purchase the drug directly through hospital pharmacies in China, and treatment must wait for formal approval and entry into the market. Recently, it was reported that Talatumumab has submitted a marketing application to the domestic drug regulatory authorities and is expected to be approved for marketing in the country in the future. This will provide new treatment options for patients with advanced tumors and may reduce the economic burden to a certain extent.

In overseas markets, talatumumab has been approved for marketing by the U.S. FDA in 2024 5 month. The drug specifications include 1mg and 10mg . The prices are about 25,000 yuan and 148,000 yuan respectively. There are currently no generic drugs to choose from. Due to the lack of domestic marketing and medical insurance support, if patients consider obtaining the drug through overseas channels, they need to follow the legal cross-border drug purchase process and ensure that the source of the drug is formal to ensure drug quality and drug safety.

Overall, the domestic drug purchase channels for talatumumab are temporarily limited, and patients need to wait patiently for the marketing approval to be completed. After the product is launched in the future, hospital pharmacies and designated purchasing channels will become the main access channels, and the medical insurance reimbursement policy is also expected to be gradually implemented along with the approval process. During this period, patients and family members should pay attention to official information and avoid purchasing drugs through informal channels to ensure treatment safety and drug effectiveness.

Keyword tag:

Tarlatamab, Tarlatamab, Imdelltra, domestic purchase, drug purchase channels, marketing application, FDA approval, overseas price, generic drugs, tumor immunotherapy

Reference materials:https://go.drugbank.com/drugs/DB17256